Cargando…

MMP-2/9-Specific Activatable Lifetime Imaging Agent

Optical (molecular) imaging can benefit from a combination of the high signal-to-background ratio of activatable fluorescence imaging with the high specificity of luminescence lifetime imaging. To allow for this combination, both imaging techniques were integrated in a single imaging agent, a so-cal...

Descripción completa

Detalles Bibliográficos
Autores principales: Rood, Marcus T.M., Raspe, Marcel, ten Hove, Jan Bart, Jalink, Kees, Velders, Aldrik H., van Leeuwen, Fijs W.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481940/
https://www.ncbi.nlm.nih.gov/pubmed/25985157
http://dx.doi.org/10.3390/s150511076
_version_ 1782378351160197120
author Rood, Marcus T.M.
Raspe, Marcel
ten Hove, Jan Bart
Jalink, Kees
Velders, Aldrik H.
van Leeuwen, Fijs W.B.
author_facet Rood, Marcus T.M.
Raspe, Marcel
ten Hove, Jan Bart
Jalink, Kees
Velders, Aldrik H.
van Leeuwen, Fijs W.B.
author_sort Rood, Marcus T.M.
collection PubMed
description Optical (molecular) imaging can benefit from a combination of the high signal-to-background ratio of activatable fluorescence imaging with the high specificity of luminescence lifetime imaging. To allow for this combination, both imaging techniques were integrated in a single imaging agent, a so-called activatable lifetime imaging agent. Important in the design of this imaging agent is the use of two luminophores that are tethered by a specific peptide with a hairpin-motive that ensured close proximity of the two while also having a specific amino acid sequence available for enzymatic cleavage by tumor-related MMP-2/9. Ir(ppy)(3) and Cy5 were used because in close proximity the emission intensities of both luminophores were quenched and the influence of Cy5 shortens the Ir(ppy)(3) luminescence lifetime from 98 ns to 30 ns. Upon cleavage in vitro, both effects are undone, yielding an increase in Ir(ppy)(3) and Cy5 luminescence and a restoration of Ir(ppy)(3) luminescence lifetime to 94 ns. As a reference for the luminescence activation, a similar imaging agent with the more common Cy3-Cy5 fluorophore pair was used. Our findings underline that the combination of enzymatic signal activation with lifetime imaging is possible and that it provides a promising method in the design of future disease specific imaging agents.
format Online
Article
Text
id pubmed-4481940
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-44819402015-06-29 MMP-2/9-Specific Activatable Lifetime Imaging Agent Rood, Marcus T.M. Raspe, Marcel ten Hove, Jan Bart Jalink, Kees Velders, Aldrik H. van Leeuwen, Fijs W.B. Sensors (Basel) Article Optical (molecular) imaging can benefit from a combination of the high signal-to-background ratio of activatable fluorescence imaging with the high specificity of luminescence lifetime imaging. To allow for this combination, both imaging techniques were integrated in a single imaging agent, a so-called activatable lifetime imaging agent. Important in the design of this imaging agent is the use of two luminophores that are tethered by a specific peptide with a hairpin-motive that ensured close proximity of the two while also having a specific amino acid sequence available for enzymatic cleavage by tumor-related MMP-2/9. Ir(ppy)(3) and Cy5 were used because in close proximity the emission intensities of both luminophores were quenched and the influence of Cy5 shortens the Ir(ppy)(3) luminescence lifetime from 98 ns to 30 ns. Upon cleavage in vitro, both effects are undone, yielding an increase in Ir(ppy)(3) and Cy5 luminescence and a restoration of Ir(ppy)(3) luminescence lifetime to 94 ns. As a reference for the luminescence activation, a similar imaging agent with the more common Cy3-Cy5 fluorophore pair was used. Our findings underline that the combination of enzymatic signal activation with lifetime imaging is possible and that it provides a promising method in the design of future disease specific imaging agents. MDPI 2015-05-12 /pmc/articles/PMC4481940/ /pubmed/25985157 http://dx.doi.org/10.3390/s150511076 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rood, Marcus T.M.
Raspe, Marcel
ten Hove, Jan Bart
Jalink, Kees
Velders, Aldrik H.
van Leeuwen, Fijs W.B.
MMP-2/9-Specific Activatable Lifetime Imaging Agent
title MMP-2/9-Specific Activatable Lifetime Imaging Agent
title_full MMP-2/9-Specific Activatable Lifetime Imaging Agent
title_fullStr MMP-2/9-Specific Activatable Lifetime Imaging Agent
title_full_unstemmed MMP-2/9-Specific Activatable Lifetime Imaging Agent
title_short MMP-2/9-Specific Activatable Lifetime Imaging Agent
title_sort mmp-2/9-specific activatable lifetime imaging agent
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481940/
https://www.ncbi.nlm.nih.gov/pubmed/25985157
http://dx.doi.org/10.3390/s150511076
work_keys_str_mv AT roodmarcustm mmp29specificactivatablelifetimeimagingagent
AT raspemarcel mmp29specificactivatablelifetimeimagingagent
AT tenhovejanbart mmp29specificactivatablelifetimeimagingagent
AT jalinkkees mmp29specificactivatablelifetimeimagingagent
AT veldersaldrikh mmp29specificactivatablelifetimeimagingagent
AT vanleeuwenfijswb mmp29specificactivatablelifetimeimagingagent